- Home
- IZTC vs BNR Comparison
IZTC vs BNR Comparison
Compare IZTC & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZTC
- BNR
- Stock Information
- Founded
- IZTC 2019
- BNR 2014
- Country
- IZTC United States
- BNR China
- Employees
- IZTC N/A
- BNR N/A
- Industry
- IZTC Biotechnology: Biological Products (No Diagnostic Substances)
- BNR Medical Specialities
- Sector
- IZTC Health Care
- BNR Health Care
- Exchange
- IZTC Nasdaq
- BNR Nasdaq
- Market Cap
- IZTC 69.5M
- BNR 73.5M
- IPO Year
- IZTC 2024
- BNR 2020
- Fundamental
- Price
- IZTC $16.21
- BNR $7.00
- Analyst Decision
- IZTC
- BNR
- Analyst Count
- IZTC 0
- BNR 0
- Target Price
- IZTC N/A
- BNR N/A
- AVG Volume (30 Days)
- IZTC 32.5K
- BNR 14.3K
- Earning Date
- IZTC 01-01-0001
- BNR 12-24-2024
- Dividend Yield
- IZTC N/A
- BNR N/A
- EPS Growth
- IZTC N/A
- BNR N/A
- EPS
- IZTC N/A
- BNR N/A
- Revenue
- IZTC N/A
- BNR $72,832,704.00
- Revenue This Year
- IZTC N/A
- BNR $52.90
- Revenue Next Year
- IZTC N/A
- BNR $48.35
- P/E Ratio
- IZTC N/A
- BNR N/A
- Revenue Growth
- IZTC 145.01
- BNR N/A
- 52 Week Low
- IZTC $8.50
- BNR $2.62
- 52 Week High
- IZTC $19.37
- BNR $9.99
- Technical
- Relative Strength Index (RSI)
- IZTC N/A
- BNR 69.32
- Support Level
- IZTC N/A
- BNR $6.03
- Resistance Level
- IZTC N/A
- BNR $7.00
- Average True Range (ATR)
- IZTC 0.00
- BNR 0.48
- MACD
- IZTC 0.00
- BNR -0.04
- Stochastic Oscillator
- IZTC 0.00
- BNR 84.21
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.